Why Arbutus Biopharma (ABUS) Stock Rose 3.13% in 10 Minutes on Oct 22, 2026
The 3.13% gain was larger than any reaction MoveSurge measured after Arbutus Biopharma headlines between Jul 24, 2026 and Oct 21, 2026; the largest of those was +1.64% in 15 minutes, on Aug 21, 2026.
- ABUS rose 3.13% in the 10 minutes after the 07:30:00 ET headline, from $4.15 to $4.28.
- 47,833 shares changed hands in those 10 minutes.
- The headline crossed in pre-market trading, 2 hours before the 9:30 ET open.
07:30:00 ET
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| ABUS | 4.15 | 4.15 | 4.35 | 4.28 | +4.82% | +3.13% |
Arbutus Biopharma (ABUS) shares rose 3.13% in the 10 minutes after this headline reached the MoveSurge news feed at 07:30:00 ET on Thursday, October 22, 2026: “Arbutus says the FDA lifted the clinical hold on its IND application for oral PD-L1 inhibitor AB-101”
ABUS in the first 10 minutes
From a reference price of $4.15 just before the headline, the stock was up 4.82% after one minute and up 3.13%, at $4.28, after 10 minutes. Part of the first-minute move came back by the 10-minute mark. 47,833 shares changed hands in those 10 minutes. The headline crossed in pre-market trading, 2 hours before the 9:30 ET open.
Earlier ABUS headlines and the measured reaction
The 3.13% gain was larger than any reaction MoveSurge measured after Arbutus Biopharma headlines between Jul 24, 2026 and Oct 21, 2026; the largest of those was +1.64% in 15 minutes, on Aug 21, 2026.
- Aug 21, 2026, 07:31 ET: “Arbutus Biopharma Plans Up To $230M Modified Dutch Auction Tender Offer At $5.00 To $5.75/Share; Expected To Commence August 24, Expire September 29” (+1.64% in 15 minutes)
- Aug 12, 2026, 07:34 ET: “Arbutus Biopharma (ABUS) Fiscal Q2 earnings results” (-0.44% in 15 minutes)
Arbutus Biopharma at a glance
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Market value | $641 million (as of Oct 23, 2026) |
| Next earnings report on the calendar | Thursday, November 12, 2026 |
Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.
What headline moved Arbutus Biopharma stock on October 22, 2026?
At 07:30:00 ET, this headline crossed: “Arbutus says the FDA lifted the clinical hold on its IND application for oral PD-L1 inhibitor AB-101”. The stock rose 3.13% in the next 10 minutes.
How far did ABUS move after the headline?
From $4.15 just before the headline to $4.28 10 minutes later, a +3.13% move.
When does Arbutus Biopharma report earnings next?
The next report on the MoveSurge earnings calendar is Thursday, November 12, 2026.
What else has moved ABUS stock recently?
The two largest measured reactions before October 22, 2026: Aug 21, 2026, Arbutus Biopharma Plans Up To $230M Modified Dutch Auction Tender Offer At $5.00 To $5.75/Share; Expected To Commence August 24, Expire September 29 (+1.64% in 15 minutes); Aug 12, 2026, Arbutus Biopharma (ABUS) Fiscal Q2 earnings results (-0.44% in 15 minutes).
Sources
-
ABUS headline and measured reaction, Oct 22, 2026
— MoveSurge
The headline as it crossed, its timestamp, and the measured price reaction reported on this page.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes price moves after the news, search, watchlists, alerts and research tools.
Create free accountGo real time Watch live headlines -- free